Influx Healthtech Ltd IPOINFLUX

The IPO opens on 18 Jun 2025 & closes on 20 Jun 2025.

Influx Healthtech Limited was originally incorporated on September 28, 2020 as a Private Limited Company as 'Influx Healthtech Private Limited' with the Registrar of Companies, Central Registration Centre. Company converted from a Private Limited to Public Limited and the name of Company was changed to Influx Healthtech Limited' and a Fresh Certificate of Incorporation upon the conversion was issued on May 23, 2022 by the Registrar of Companies, Mumbai. Influx Healthtech Limited is a a Mumbai-based healthcare product-focused company that has carved a niche in manufacturing Soft Gelatin, Tablets, Capsules, Liquid Orals, Oral Powders, Liquid fill capsules, Effervescent tablets, Nutra Pallets, Protein Bars, Cookies, Jellies/ Gummies, External preparations like Creams, Gels, Ointments, External Oils, Soaps, etc. for the Nutraceuticals, Cosmetics, Ayurvedic / Herbal, Veterinary Feed Supplements and Homecare segment. The Company is majorly involved in the manufacturing of Dietary/Nutritional Supplements, Gym/Sports Supplements, Veterinary Feeds, Liquid fill capsules, Ayurvedic products and homecare products for small and medium marketing and distribution brands. It specialized in manufacturing of dietary and nutritional supplements and which supports their clients during the product development phase and manufacturing of products which can further be processed into distribution and marketing by different brands. The Company operates three manufacturing plants located in Thane, Maharashtra, which are certified with GMP, HACCP, ISO 22000, and Halal, and are equipped with advanced machinery, a quality control department, and a skilled workforce. It works as a Contract Development and Manufacturing Organization (CDMO), which is a third-party manufacturer. It specialize in a diverse products across several segments, including Dietary/Nutritional Supplements, Cosmetics, Ayurvedic / Herbal, Veterinary Feed Supplements, and Homecare segment. This includes the production of Active Pharmaceutical Ingredients (APIs) and the manufacturing of finished dosage forms such as tablets, capsules, and injectables. The Company came up with a public issue of 61,00,800 equity shares of face value of Rs 10 each by raising funds aggregating to Rs 58.56 crore comprising a fresh issue of 50,00,400 equity shares aggregating to Rs 48 Crore and 11,00,400 equity shares aggregating to Rs 10.56 Crore via offer for sale in June, 2025.

Influx Healthtech Ltd IPO will close on 20 Jun 2025.

<ul><li>Diverse client base with longstanding CDMO relationships.</li><li>Well versed and equipped advanced manufacturing facilities with global accreditations.</li><li>Large and rapidly growing R&D capabilities across our product portfolio.</li><li>Experienced Promoter and management team with strong industry expertise and successful track record.</li><li>Robust Quality Assurance & Control practices.</li><li>Proven Track record of growth and profitability.</li></ul>

<table class="table"> <thead> <tr> <th>S.No</th> <th>Promoters Name</th> <th>Pre Issue Shares</th> <th>Pre Issue Percentage</th> <th>Post Issue Shares</th> <th>Post Issue Percentage</th> </tr> </thead> <tbody> <tr> <td>1</td> <td>Munir Abdul Ganee Chandniwala</td> <td>17242500</td> <td>95</td> <td>16142100</td> <td>69.73</td> </tr> <tr> <td>2</td> <td>Shirin Munir Ahmed Chandniwala</td> <td>880638</td> <td>4.85</td> <td>880638</td> <td>3.8</td> </tr> <tr> <td>3</td> <td>Abdul Ganee Abdul Rasul Chandn</td> <td>726</td> <td>---</td> <td>726</td> <td>---</td> </tr> </tbody> </table>

<ul><li>The Company is reliant on the demand from the nutraceutical industry for a significant portion of its revenue. Any downturn in the nutraceutical industry or an inability to increase or effectively manage its sales could have an adverse impact on the Company's business and results of operations.</li><li>Its existing manufacturing facility are concentrated in a single region i.e., Palghar, Thane, Maharashtra and the inability to operate and grow its business in this particular region may have an adverse effect on its business, financial condition, results of operations, cash flows and future business prospects.</li><li>The Company is dependent on few numbers of customers for sales. Loss of any of this large customer may affect its revenues and profitability.</li><li>The company has historically derived, and may continue to derive, a signification of its supply from top 10 Suppliers. Also, the Company has not entered into long-term agreements with these suppliers. In the event the company is unable to procure adequate amounts of raw materials, at competitive prices its business, results of operations and financial condition may be adversely affected.</li><li>Too much Geographical concentration of its Business on specific location can impact the company Business.</li><li>Its reliance on certain industries for a significant portion of its sales could have an adverse effect on its business.</li><li>The company has not taken any steps to order the machinery/equipment required for the proposed expansion. In the event of any delay in placing the orders, or in the event the vendors are not able to provide the equipment / machineries in a timely manner, or at all, the same may result in time and cost over-runs.</li><li>Its business activities are exposed to fluctuations in the prices of raw materials.</li><li>Its may face several risks associated with the construction of the building of the Proposed Expansion, which could hamper its growth, prospects, cash flows and business and financial condition.</li><li>Its Registered Office, Factory Units and Godown is located on premises which are not owned by it and has been obtained on license basis from the promoters of the company. Disruption of its rights as licensee/ lessee or termination of the agreements with its licensors/ lessors (promoters) may adversely impact its operations and, consequently, its business, financial condition and results of operations.</li><li>Its expansion into new product categories and business verticals and a substantial increase in the number of products offered may expose it to new challenges and more risks. Its efforts to introduce new formulation and combination are dependent on the success of its formulation development team initiatives.</li><li>There are certain discrepancies and non-compliances noticed in some of its corporate records relating to forms filed with the Registrar of Companies, taxation authorities and other public authorities. Any penalty or action taken by any regulatory authorities in future for noncompliance with provisions of all applicable law could impact on the financial position of the Company to that extent.</li><li>Optimal Capacity utilization of its manufacturing capacities and Information relating to the installed manufacturing capacity, actual production and capacity utilization of the manufacturing units included in this Offer Document are based on various assumptions. A decline in market demand or increased competition could negatively impact its sales and profitability.</li><li>The company does not possess an Ayush license which is required for the manufacturing of Ayurveda, Yoga and Naturopathy, Unani, Siddha, and Homeopathy products by the Ministry of Ayush.</li><li>There have been certain instances of delays in payment of statutory dues by the Company in the past. Any delay in payment of statutory dues by the Company in the future may result in the imposition of penalties and in turn may have an adverse effect on the Company's business, financial condition, results of operation and cash flows.</li><li>Insufficient Verifiable Documentation for Key Directors' Experience may Pose Governance Risks.</li><li>Its manufacturing activities are dependent upon availability of Skilled and Unskilled labour.</li><li>Its funding requirements and the proposed deployment of Net Proceeds have not been appraised by any bank or financial institution or any other independent agency and its management will have broad discretion over the use of the Net Proceeds.</li><li>The Company have not identified any alternate source of funding and hence any failures or delay on the part to mobilize the required resources or any shortfall in the Issue proceeds may delay the implementation schedule.</li><li>The availability of counterfeit drugs, such as drugs passed off by others as its products, could adversely affect its goodwill and results of operations.</li><li>There may be potential conflicts of interest if its Promoters or Directors get involved in any business activities that compete with or are in the same line of activity as its business operations.</li><li>The company relies on third-party transportation providers for both procurement of its raw materials and distribution of the company products. Any failures by any of its transportation providers to deliver its raw materials or its products on time, or in good condition, or at all, may adversely affect its business, financial condition and results of operations.</li><li>Its Promoter, Mr. Munir Abdul Ganee Chandniwala and Ms. Shirin Munir Ahmed Chandniwala, plays a key role in its functioning and the company heavily relies on their knowledge and experience in operating its business and therefore, it is critical for its business that the company Promoter remain associated with it.</li><li>The Company has in the past entered into related-party transactions and may continue to do so in the future.</li><li>The improper handling, processing or storage of its products or raw materials, or spoilage of and damage to such products or raw materials, or any real or perceived contamination in its products or raw materials, could subject it to regulatory action, damage its reputation and have an adverse effect on its business, results of operations and financial condition.</li><li>The company customer's brands and reputation are critical to the success of its business and may be adversely affected due to various reasons, which could have an adverse effect on its business, financial condition, cash flows and results of operations.</li><li>Product liability claims and product recalls could harm its reputation, business, financial condition, cash flows and results of operations.</li><li>The company is dependent on its vendors to sell or distribute its products to end consumer, and also on third party technology providers for certain aspects of its operations. Any disruptions or inefficiencies in these operations may adversely affect its business, financial condition, cash flows and results of operations.</li><li>There are potential risks associated with the protection, enforcement, and defense of its intellectual property rights, and how could these risks impact its business operations and financial performance.</li><li>If the company is unable to maintain an effective system of internal controls, its may not be able to successfully manage or accurately report its financial risks.</li><li>The ability to pay dividends in the future will depends on the earnings, financial condition, working capital requirements, capital expenditures and restrictive covenants of the financing arrangements.'</li><li>The manufacturing activities are subject to risks of operational hazards and can cause injury to people or property in certain circumstances.</li><li>The company relies on its information technology systems in managing its supply chain, logistics and other integral parts of its business. Any failures in its information technology systems could adversely affect its financial condition, cash flows and results of operations.</li><li>The Company is exposed to counterparty credit risk and any delay in receiving payments or nonreceipt of payments.</li><li>The Company relies extensively on the systems, including quality assurance and quality control systems to maintain the quality of the products.</li><li>Environmental, health, employee and safety laws and regulations may expose it to liability and result in an increase of its costs and a decrease in its profits.</li><li>The industry in which the Company operates is capital intensive, and they may need to seek additional financing in the future to support the growth strategies.</li><li>The company has high working capital requirements. Its inability to meet the company working capital requirements may have a material adverse effect on its business, financial condition and results of operations.</li><li>A shortage or non-availability of essential utilities (such as electricity, water) or essential services (such as railway network, road networks, etc.) could adversely affect the Company's results of operations and financial condition.</li><li>The Company has not created provisions for contingent liability. Any unexpected obligations in future could affect its future cash flows.</li><li>The company is subject to foreign currency exchange rate fluctuations which could have a material and adverse effect on its results of operations and financial conditions.</li><li>Any of Directors or KMPs of the Company does not possess experience of Listed Company.</li><li>The company operates in a highly competitive industry and its failures to compete effectively could have a negative impact on the success of its business and/or impact the company margins.</li><li>The company requires certain approvals and licenses in the ordinary course of business, and the failures to obtain or retain them in a timely manner all may adversely affect its operations.</li><li>High merchandise returns or interruption in its shipping operations could negatively impact the company business.</li><li>Some of the details mentioned in the respective KYC Documents of persons forming part of Promoter group are not same in all KYC documents.</li><li>Sale of Equity Shares by its Promoters or other significant shareholder(s) may adversely affect the Trading price of the Equity Shares.</li><li>The Promoters and Promoter Group will continue to retain control over the Company after completion of the Offer, which will allow them to influence the outcome of matters submitted for the approval of the shareholders.</li><li>The Company will not receive any proceeds from the Offer for Sale.</li><li>The nature of its business exposes it to liability claims and contract disputes and its indemnities may not adequately protect it. Any liability in excess of its reserves or indemnities could result in additional costs, which would reduce its profits.</li><li>Any adverse change in regulations governing its products and the products of the company customers, may adversely impact its business prospects and results of operations.</li><li>The company conduct its business activities on a purchase order basis and therefore, have not entered into long-term agreements with its customers.</li><li>Its insurance coverage may not adequately protect the company against all material hazards, which may adversely affect its business, results of operations and financial condition.</li><li>Malpractices by some players in the industry affect overall performance of emerging companies.</li><li>The company is not largely engaged in advertising, marketing, and promotional programs for its nutritional products.</li><li>Its may pursue strategic acquisitions for inorganic growth. However, the integration of such acquisitions could result in operating difficulties, dilution and other adverse consequences.</li><li>The company has in this Prospectus included certain non-GAAP financial measures and Key Performance Indicators ("KPIs") that may vary from any standard methodology that is applicable across its industry. The company relies on certain assumptions and estimates to calculate such measures, therefore such measures may not be comparable with financial, operational or industry-related statistical information of similar nomenclature computed and presented by other similar companies.</li><li>The Company /Promoters/Directors/Promoter Group/Group Companies is involved in certain legal proceeding(s) and potential litigations. Any adverse decision in such proceeding(s) may render them liable to liabilities/penalties.</li><li>The average cost of acquisition of Equity Shares by its Promoters is lower than the issue price.</li><li>The company cannot guarantee the accuracy or completeness of facts and other statistics with respect to India, the Indian economy and its industry contained in this Red Herring Prospectus.</li><li>Unauthorized Use or Disclosure of Confidential Information could have negative impact on the overall performance of the Company.</li><li>Significant disruptions in our information technology systems or breaches of data security could affect its business and reputation.</li><li>The Company has availed Rs. 21.92 Lakh as unsecured loan which are repayable on demand. Any demand from the lenders for repayment of such unsecured loan may affect its financial condition.</li><li>Its business and operations could be adversely impacted by labor shortages, strikes, regulatory changes, wage demands, or industrial accidents at its worksites.</li></ul>

The Issue type of Influx Healthtech Ltd is Book Building - SME.

The minimum application for shares of Influx Healthtech Ltd is 1200.

The total shares issue of Influx Healthtech Ltd is 6100800.

Initial public offer of 61,00,800 equity shares of face value of Rs. 10/- each (the "Equity Shares") of Influx Heathtech Limited ("the Company" or "IHL" or "the Issuer") at an offer price of Rs. 96/- per equity share for cash, aggregating Rs. 58.57 crores ("Public Offer") comprising of a fresh offer of 50,00,400 equity shares aggregating to Rs. 48.00 crores (the "Fresh Offer") and an offer for sale of 11,00,400 equity shares by the promoter selling shareholder, Munir Abdul Ganee Chandniwala ("Offer for Sale") aggregating to Rs. 10.56 crores, (Hereinafter Refferd as "Promoter Selling Shareholder") out of which 3,06,000 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 96/- per equity share for cash, aggregating Rs. 2.94 crores will be reserved for subscription by the market maker to the offer (the "Market Maker Reservation Portion"). The public offer less market maker reservation portion i.e. offer of 57,94,800 equity shares of face value of Rs. 10/- each, at an offer price of Rs. 96/- per equity share for cash, aggregating Rs. 55.63 crores is herein after referred to as the "Net Offer". The public offer and net offer will constitute 26.35 % and 25.03 % respectively of the post-offer paid-up equity share capital of the company.